US$ 26.83
glp-1 shortness of breath Glucagon-like peptide-1 receptor: mechanisms and advances in therapy shortness of breath glp 1
Description
This unique presentation of both NAWE and TIND in a single patient following GLP-1 agonist use warrants careful consideration of the potential central and peripheral neurological sequelae of these increasingly prevalent medications and emphasizes the need for heightened clinical awareness and appropriate monitoring strategies

These numbers are broadly comparable to semaglutide, but the intensity appears somewhat greater, likely because the glucagon component adds an additional source of gastrointestinal stimulation on top of the GLP-1 effects

doi: 10.1111/apt.70196, 7

If Mounjaro causes significant changes in blood sugar levels, it might contribute to muscle spasms, including those affecting the eyelids

PMID: 37780624

Semaglutide does not directly cause depression in most users